Structured reviews will accelerate ANDAs

Testing and implementing a more structured, computer-aided assessment process for abbreviated new drug applications (ANDAs) will enable the US Food and Drug Administration (FDA) to accelerate approvals on their first review cycle, according to Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER).